Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry refers to the concurrent administration of two separate vaccines—Japanese encephalitis (JE) vaccine and hepatitis A (HepA) vaccine. The JE vaccine is an inactivated viral vaccine used to prevent infection by the Japanese encephalitis virus, primarily indicated for travelers to endemic areas and laboratory workers. It works by inducing the body’s immune system to produce protective antibodies against the JE virus[7]. The HepA vaccine is also an inactivated viral preparation that induces immunity against hepatitis A infection. Both vaccines are typically administered as intramuscular injections. Clinical studies have shown that co-administration of these two vaccines does not significantly interfere with their safety or immunogenicity profiles; each maintains its effectiveness when given at different injection sites during the same visit[1][5]. There are no known combination products containing both antigens; rather, this refers to simultaneous administration of individual licensed products.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Japanese encephalitis vaccine + hepatitis A vaccine.